サンプル依頼リスト カート
  • English
市場調査レポート
商品コード
1716265

Gタンパク質共役受容体 (GPCR) 標的化：各種技術と世界市場

G-Protein Coupled Receptor (GPCR) Targeting: Technologies and Global Markets

出版日
発行
BCC Research
ページ情報
英文 107 Pages
納期
即納可能 即納可能とは
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.64円
Gタンパク質共役受容体 (GPCR) 標的化：各種技術と世界市場
出版日: 2025年04月23日
発行: BCC Research
ページ情報: 英文 107 Pages
納期: 即納可能 即納可能とは
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界のGタンパク質共役受容体 (GPCR) 標的化の市場規模は、2024年の44億米ドルから、予測期間中はCAGR6.8%で推移し、2029年末には61億米ドルに達すると予測されています。

北米市場は、2024年の18億米ドルから、予測期間中はCAGR 5.8%で推移し、2029年末には23億米ドルに達すると予測されています。欧州市場は、2024年の12億米ドルから、予測期間中は7.1%のCAGRで推移し、2029年末には18億米ドルに達すると予測されています。

当レポートでは、世界のGタンパク質共役受容体 (GPCR) 標的化の市場を調査し、市場概要、市場影響因子および市場機会の分析、法規制環境、新興技術および技術開発の動向、市場規模の推移・予測、各種区分・地域別の詳細分析、競合情勢、主要企業のプロファイルなどをまとめています。

目次

第1章 エグゼクティブサマリー

  • 市場見通し
  • 調査範囲
  • 市場サマリー

第2章 市場概要

  • 概要
  • GPCRの種類
  • GPCRの細胞応答：イントロダクション
  • 疾患生理学におけるGPCRの重要性
  • 規制面

第3章 市場力学

  • 概要
  • 市場促進要因
  • 慢性疾患の発生率の上昇
  • GPCR薬の需要増加
  • GPCR研究における技術的進歩
  • 市場抑制要因
  • 創薬の課題
  • GPCR構造研究の限界
  • 市場機会
  • 個別化癌治療

第4章 新興技術と開発

  • 概要
  • 新興技術
  • 新しいスクリーニング技術
  • GPCR標的創薬における構造解析
  • GPCR標的創薬における実験スクリーニング
  • 特許分析
  • 特許レビュー：出願人別

第5章 市場セグメンテーション分析

  • 市場概要
  • セグメンテーションの内訳
  • GPCR標的化：各種技術と世界市場
  • 市場分析：アッセイタイプ別
  • cAMPアッセイとcGMPアッセイ
  • カルシウム機能アッセイ
  • アレスチン機能アッセイ
  • 放射性リガンド結合およびGTPガンマS機能アッセイ
  • レポーター遺伝子アッセイ
  • その他
  • 市場分析：製品タイプ別
  • 細胞株
  • 検出キット
  • 細胞培養試薬
  • リガンド
  • 市場分析：用途別
  • 腫瘍/癌
  • 心血管疾患
  • 中枢神経系疾患
  • 呼吸器疾患
  • その他
  • 地理的内訳
  • 市場分析：地域別
  • 北米
  • 欧州
  • アジア太平洋
  • その他の地域

第6章 競合情報

  • 概要
  • 業界企業ランキング
  • 業界におけるベンチャー資金調達

第7章 GPCR標的技術産業における持続可能性：ESGの観点

  • 世界のGPCR産業における持続可能性
  • ESGリスクと格付け：データの理解
  • BCCによる見解

第8章 付録

  • 出典
  • 略語
  • 企業プロファイル
  • AGILENT TECHNOLOGIES INC.
  • BD
  • DANAHER CORP.
  • ENZO BIOCHEM INC.
  • EPICS THERAPEUTICS
  • EUROFINS SCIENTIFIC
  • INTERAX BIOTECH AG
  • MERCK KGAA
  • ORION BIOTECHNOLOGY CANADA LTD.
  • PROMEGA CORP.
  • QIAGEN
  • REVVITY
  • TECTONIC THERAPEUTIC
  • THERMO FISHER SCIENTIFIC INC.
  • WUXI APPTEC
図表

List of Tables

  • Summary Table : Global Market for GPCR-Targeting Technologies, by Region, Through 2029
  • Table 1 : Number of New Cases and Deaths Due to Various Cancers, Globally, 2022
  • Table 2 : U.S. NIH Funding for Various Diseases and Conditions, 2019-2023
  • Table 3 : FDA-Approved Drugs Targeting GPCR, 2020-2024
  • Table 4 : Patents Issued for GPCRs, by Applicant, January 2023-December 2024
  • Table 5 : Global Market for GPCR-Targeting Technologies, Through 2029
  • Table 6 : Global Market for GPCR Targeting Technologies, by Assay Type, Through 2029
  • Table 7 : Global Market for GPCR-Targeting Technologies, by Product Type, Through 2029
  • Table 8 : Global Market for GPCR-Targeting Technologies, by Application, Through 2029
  • Table 9 : GPCRs, Ligands and Their Locations in the Body
  • Table 10 : GPCR Families and Their Role in CNS Disorders
  • Table 11 : Glucocorticoid Effects Mediated by Transactivation Mechanisms in Airway Structural Cells
  • Table 12 : Global Market for GPCR-Targeting Technologies, by Region, Through 2029
  • Table 13 : North American Market for GPCR-Targeting Technologies, by Country, Through 2029
  • Table 14 : European Market for GPCR-Targeting Technologies, by Country, Through 2029
  • Table 15 : APAC Market for GPCR-Targeting Technologies, by Country, Through 2029
  • Table 16 : ROW Market for GPCR-Targeting Technologies, by Subregion, Through 2029
  • Table 17 : Market Rankings of Leading Companies in the GPCR-Targeting Technologies Industry, 2023
  • Table 18 : Funding for GPCR-Targeting Technologies Companies, 2022-2024
  • Table 19 : ESG Rankings for Major GPCR Companies, 2024*
  • Table 20 : Sources Used in this Report
  • Table 21 : Abbreviations Used in this Report
  • Table 22 : Agilent Technologies Inc.: Company Snapshot
  • Table 23 : Agilent Technologies Inc.: Financial Performance, FY 2022 and 2023
  • Table 24 : Agilent Technologies Inc.: Product Portfolio
  • Table 25 : BD: Company Snapshot
  • Table 26 : BD: Financial Performance, FY 2023 and 2024
  • Table 27 : BD: Product Portfolio
  • Table 28 : Danaher Corp.: Company Snapshot
  • Table 29 : Danaher Corp.: Financial Performance, FY 2022 and 2023
  • Table 30 : Danaher Corp.: Product Portfolio
  • Table 31 : Enzo Biochem Inc.: Company Snapshot
  • Table 32 : Enzo Biochem Inc.: Financial Performance, FY 2023 and 2024
  • Table 33 : Enzo Biochem Inc.: Product Portfolio
  • Table 34 : Epics Therapeutics: Company Snapshot
  • Table 35 : Epics Therapeutics: Product Portfolio
  • Table 36 : Eurofins Scientific: Company Snapshot
  • Table 37 : Eurofins Scientific: Financial Performance, FY 2022 and 2023
  • Table 38 : Eurofins Scientific: Product Portfolio
  • Table 39 : InterAx Biotech AG: Company Snapshot
  • Table 40 : InterAx Biotech AG: Product Portfolio
  • Table 41 : Merck KGaA: Company Snapshot
  • Table 42 : Merck KGaA: Financial Performance, FY 2022 and 2023
  • Table 43 : Merck KGaA: Product Portfolio
  • Table 44 : Orion Biotechnology Canada Ltd.: Company Snapshot
  • Table 45 : Orion Biotechnology Canada Ltd.: Product Portfolio
  • Table 46 : Promega Corp.: Company Snapshot
  • Table 47 : Promega Corp.: Product Portfolio
  • Table 48 : Promega Corp.: News/Key Developments, 2023 and 2024
  • Table 49 : Qiagen: Company Snapshot
  • Table 50 : Qiagen: Financial Performance, FY 2022 and 2023
  • Table 51 : Qiagen: Product Portfolio
  • Table 52 : Revvity: Company Snapshot
  • Table 53 : Revvity: Financial Performance, FY 2022 and 2023
  • Table 54 : Revvity: Product Portfolio
  • Table 55 : Revvity: News/Key Developments, 2021
  • Table 56 : Tectonic Therapeutic: Company Snapshot
  • Table 57 : Tectonic Therapeutic: Product Portfolio
  • Table 58 : Tectonic Therapeutic: News/Key Developments, 2024
  • Table 59 : Thermo Fisher Scientific Inc.: Company Snapshot
  • Table 60 : Thermo Fisher Scientific Inc.: Financial Performance, FY 2022 and 2023
  • Table 61 : Thermo Fisher Scientific Inc.: Product Portfolio
  • Table 62 : Wuxi AppTec: Company Snapshot
  • Table 63 : Wuxi AppTec: Financial Performance, FY 2022 and 2023
  • Table 64 : Wuxi AppTec: Product Portfolio

List of Figures

  • Summary Figure : Global Market Shares for GPCR-Targeting Technologies, by Region, 2023
  • Figure 1 : Snapshot of the Market Dynamics for GPCR-Targeting Technologies
  • Figure 2 : Global Market Shares for GPCR-Targeting Technologies, by Assay Type, 2023
  • Figure 3 : Global Market Shares for GPCR-Targeting Technologies, by Product Type, 2023
  • Figure 4 : Global Market Shares for GPCR-Targeting Technologies, by Application, 2023
  • Figure 5 : Global Market Shares for GPCR-Targeting Technologies, by Region, 2023
  • Figure 6 : North American Market Shares for GPCR-Targeting Technologies, by Country, 2023
  • Figure 7 : European Market Shares for GPCR-Targeting Technologies, by Country, 2023
  • Figure 8 : APAC Market Shares for GPCR-Targeting Technologies, by Country, 2023
  • Figure 9 : ROW Market Shares for GPCR-Targeting Technologies, by Subregion, 2023
  • Figure 10 : Agilent Technologies Inc.: Revenue Share, by Business Unit, FY 2023
  • Figure 11 : Agilent Technologies Inc.: Revenue Share, by Country/Region, FY 2023
  • Figure 12 : BD: Revenue Share, by Business Unit, FY 2024
  • Figure 13 : BD: Revenue Share, by Country/Region, FY 2024
  • Figure 14 : Danaher Corp.: Revenue Share, by Business Unit, FY 2023
  • Figure 15 : Danaher Corp.: Revenue Share, by Country/Region, FY 2023
  • Figure 16 : Enzo Biochem Inc.: Revenue Share, by Country/Region, FY 2023
  • Figure 17 : Eurofins Scientific: Revenue Share, by Business Unit, FY 2023
  • Figure 18 : Eurofins Scientific: Revenue Share, by Country/Region, FY 2023
  • Figure 19 : Merck KGaA: Revenue Share, by Business Unit, FY 2023
  • Figure 20 : Merck KGaA: Revenue Share, by Country/Region, FY 2023
  • Figure 21 : Qiagen: Revenue Share, by Business Unit, FY 2023
  • Figure 22 : Qiagen: Revenue Share, by Country/Region, FY 2023
  • Figure 23 : Revvity: Revenue Share, by Business Unit, FY 2023
  • Figure 24 : Revvity: Revenue Share, by Country/Region, FY 2023
  • Figure 25 : Thermo Fisher Scientific Inc.: Revenue Share, by Business Unit, 2023
  • Figure 26 : Thermo Fisher Scientific Inc.: Revenue Share, by Country/Region, 2023
  • Figure 27 : Wuxi AppTec: Revenue Share, by Business Unit, 2023
  • Figure 28 : Wuxi AppTec: Revenue Share, by Country/Region, 2023
目次
Product Code: BIO136B

The global G protein-coupled receptor (GPCR) market is expected to grow from $4.4 billion in 2024 and is projected to reach $6.1 billion by the end of 2029, at a compound annual growth rate (CAGR) of 6.8% during the forecast period of 2024 to 2029.

The North American GPCR market is expected to grow from $1.8 billion in 2024 and is projected to reach $2.3 billion by the end of 2029, at a CAGR of 5.8% during the forecast period of 2024 to 2029.

The European GPCR market is expected to grow from $1.2 billion in 2024 and is projected to reach $1.8 billion by the end of 2029, at a CAGR of 7.1% during the forecast period of 2024 to 2029.

Report Scope:

This report on the global market for G protein-coupled receptor (GPCR) targeting technologies analyzes the current landscape, including market size and growth trends and segments the market by assay type, product type, application and region. Assay categories include cAMP assays and cGMP assays, calcium functional assays, arrestin functional assays, radioligand binding and GTPgammaS functional assays, reporter gene assays and others. Product types include cell lines, detection kits, cell culture reagents and ligands. Applications include oncology, cardiovascular diseases (CVDs), central nervous system diseases, respiratory diseases and others.

The regions looked at are North America (the U.S., Canada and Mexico), Europe (Germany, the U.K., France, Italy, Spain, Russia and Rest of Europe), Asia-Pacific (China, Japan, India, South Korea, Australia, Singapore and Rest of APAC) and the Rest of the World (South America, the Middle East and Africa). The report also includes profiles of leading companies and discusses industry trends, significant products, mergers and acquisitions, and other collaborations or partnerships.

In-text citations are given by the author and the year that the research or study was published. More details on these sources can be found in the table listing them in the Appendix.

Report Includes:

  • 22 data tables and 43 additional tables
  • An analysis of the global market and technologies for G-protein coupled receptor (GPCR) targeting
  • Analyses of the global market trends, with data from 2021-2023, estimates for 2024, and projections of compound annual growth rates (CAGRs) through 2029
  • Evaluation of the market potential for GPCR targeting technology, industry growth drivers, and forecasts for this market's segments and sub-segments
  • Estimates of the market size and revenue forecast for the global GPCR targeting technology market in USD millions, and a corresponding market share analysis by assay type, product type, application and region
  • Discussion of the major market dynamics and shifts, and the regulations, industry challenges and macroeconomic factors affecting the demand for GPCR targeting technology over the coming years
  • A look at the recent technological breakthroughs in the use of GPCR targeting technology, and how it has propelled the rapid growth in genetic engineering and advanced pharmacological research
  • Review of the patent filings and research publications for innovations in GPCR targeting technology
  • Discussion on the industry's ESG challenges and practices
  • Identification of the companies that are best positioned to meet this demand because of their proprietary technologies, strategic alliances or other advantages
  • Insights into the industry structure for GPCR targeting technology, the competitive landscape, clinical trials and ongoing research activity
  • Profiles of the major players in the industry, including Promega Corp., Revvity Inc., Thermo Fisher Scientific Inc., Enzo Biochem Inc., and Danaher Corp.

Table of Contents

Chapter 1 Executive Summary

  • Market Outlook
  • Scope of Report
  • Market Summary

Chapter 2 Market Overview

  • Overview
  • Types of GPCRs
  • Introduction of GPCR Cellular Responses
  • Importance of GPCRs in Disease Physiology
  • Regulatory Aspect

Chapter 3 Market Dynamics

  • Overview
  • Market Drivers
  • Rising Incidence of Chronic Diseases
  • Growing Demand for GPCR Drugs
  • Technological Advances in GPCR Research
  • Market Restraints
  • Challenges of Drug Discovery
  • Limitations of GPCR Structural Studies
  • Market Opportunities
  • Personalized Cancer Therapy

Chapter 4 Emerging Technologies and Developments

  • Overview
  • Emerging Technologies
  • Novel Screening Technology
  • Structural Analysis in GPCR-Targeted Drug Discovery
  • Experimental Screening in GPCR-Targeted Drug Discovery
  • Patent Analysis
  • Patent Review, by Applicant

Chapter 5 Market Segmentation Analysis

  • Market Overview
  • Segmentation Breakdown
  • GPCR-Targeting: Technologies and Global Markets
  • Market Analysis by Assay Type
  • cAMP Assays and cGMP Assays
  • Calcium Functional Assays
  • Arrestin Functional Assays
  • Radioligand-Binding and GTPgammaS Functional Assays
  • Reporter Gene Assays
  • Other Assays
  • Market Analysis by Product Type
  • Cell Lines
  • Detection Kits
  • Cell Culture Reagents
  • Ligands
  • Market Analysis by Application
  • Oncology/Cancers
  • Cardiovascular Diseases
  • Central Nervous System Diseases
  • Respiratory Diseases
  • Other Diseases
  • Geographic Breakdown
  • Market Analysis by Region
  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World

Chapter 6 Competitive Intelligence

  • Overview
  • Ranking of Companies in the Industry
  • Venture Fundings in the Industry

Chapter 7 Sustainability in the GPCR-Targeting Technologies Industry: An ESG Perspective

  • Sustainability in the Global GPCR Industry
  • ESG Risks and Ratings: Understanding the Data
  • BCC Research Viewpoint

Chapter 8 Appendix

  • Sources
  • Abbreviations
  • Company Profiles
  • AGILENT TECHNOLOGIES INC.
  • BD
  • DANAHER CORP.
  • ENZO BIOCHEM INC.
  • EPICS THERAPEUTICS
  • EUROFINS SCIENTIFIC
  • INTERAX BIOTECH AG
  • MERCK KGAA
  • ORION BIOTECHNOLOGY CANADA LTD.
  • PROMEGA CORP.
  • QIAGEN
  • REVVITY
  • TECTONIC THERAPEUTIC
  • THERMO FISHER SCIENTIFIC INC.
  • WUXI APPTEC